Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,555,555 | $351,836,637 | 3.16% | |
| 2. | Deep Track Capital David Kroin | 4,740,072 | $254,399,664 | +11% | 3.7% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,366,823 | $180,697,390 | -3% | 4.62% |
| 4. | OrbiMed Advisors Samuel Isaly | 2,209,400 | $118,578,498 | +50% | 2.2% |
| 5. | Driehaus Capital Richard Driehaus | 1,553,219 | $83,361,264 | -2% | 0.48% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,760 | $930,595 | 0.08% | |
| 2. | 1,730 | $54,097 | 0% | |
| 3. | 857 | $26,798 | 0% |